我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

抽象的

Methylation markers in colorectal cancer: current updates and future prospective

Ahmed Khamas Alhumairi

Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second in females and the fourth most common cause of death worldwide with a major impact on societies across the globe. Powerful avoidance techniques that incorporate early analytic tests through screening programs are important to diminish malignancy frequency and mortality.Both genetic and epigenetic alterations can cooperate in CRC initiation and progression. DNA methylation, histone modifications, and microRNA expression are epigenetic alterations in cancer. Aberrant DNA methylation changes, that are both stable and inheritable, occur early in carcinogenesis, thus it could be used as a noninvasive biomarkers for early detection and prognosis of cancers. In addition, methylation biomarkers can help in predicting response or resistance to chemotherapy.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。